Systemic Lupus Erythematosus Market

SKU: DMPH51 | Last Updated On: Sep 25 2021 | No. of Pages: 180 | Available Formats

> Global Systemic Lupus Erythematosus Market Expected to reach a high CAGR of 7.0% By 2028: DataM Intelligence

Global Systemic Lupus Erythematosus Market is segmented By Drug Class (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Biologics, Others), By Mode of Delivery (Intravenous, Sub-cutaneous, Oral, Topical), By Distribution Channel (Retail pharmacies, Hospitals, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

Market Overview

The Global Systemic Lupus Erythematosus Market is expected to grow at a CAGR of 7.0% during the forecasting period (2021-2028).

  • Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune disease with signs and symptoms that can affect any part of the body, such as skin, joints, and organs.
  • The disease is more common in women and usually affects individuals in the age group of 25 to 45.
  • At least 5 million people worldwide suffer from a form of lupus.

Market Growth and Trends:

  • The Global Systemic Lupus Erythematosus market is expected to reach USD 3.2 billion by 2025.
  • Primary market drivers include increased incidence of autoimmune diseases, a robust pipeline with different molecules in clinical development, increasing R&D investment in SLE drugs and raising awareness among people about SLE treatments.
  • However, lack of understanding about the pathogenesis of the disease, use of off-label drugs, slow market uptake of Benlysta is some of the significant factors affecting market growth.
  • A high level of unmet need exists in the SLE market for therapies that can reduce the use of corticosteroids and improve the quality of life of patients.

Market Segmentation

  • Global Systemic Lupus Erythematosus market report segments the market by drug class, by mode of delivery, and by region.
  • Based on the type of treatment provided, the market is segmented into Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic And Immunosuppressive Drugs, Biologics. Anti-malarials, steroids, and other immunosuppressive agents will continue to dominate the market.
  • Based on the distribution channel by which drugs can be obtained, the market is segmented into hospitals, retail pharmacies, and online pharmacies.
    • Hospitals, followed by retail pharmacies will account for significant market share.
  • Based on the mode of delivery, the market is further segmented into oral, intravenous, topical and subcutaneous routes.
  • Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
    • North America accounts for a dominant share regarding revenue, followed by Europe due to a high incidence rate of SLE.
    • In the North America region, the US is the largest market.
    • The Lupus Foundation of America estimates that 1.5 million Americans have a form of lupus.
  • Asia-Pacific presents the enormous opportunity for market expansion due to the increasing prevalence of asthma that has resulted from high levels of air pollution, rapid urbanization, the rise in smoking population, and changing lifestyle.

The Scope of the Report

  • The report also profiles the following companies in Systemic Lupus Erythematosus market – Anthera Pharmaceuticals Inc., Eli Lilly, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.

By Drug Class

  • Antimalarial Drugs
  • Non-Steroidal Anti-Inflammatory Drugs
  • Cytotoxic And Immunosuppressive Drugs
  • Biologics
  • Others

By Mode of Delivery

  • Intravenous
  • Sub-cutaneous
  • Oral
  • Topical

By Distribution channel

  • Hospitals
  • Retail pharmacies
  • Online pharmacies

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
  • North America (The USA, Canada, Mexico)
  • South America (Brazil, Argentina, Rest of South America)
  • Rest of the World

Why purchase the report?

  • Visualize the composition of Systemic Lupus Erythematosus market across each indication, regarding type and treatment options, highlighting the vital commercial assets and players.
  • Identify commercial opportunities in the market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the Systemic Lupus Erythematosus market – level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for crucial Systemic Lupus Erythematosus products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers


Table of Contents

Chapter 1 – Global Systemic Lupus Erythematosus Market – Methodology and Scope  

1.1 Research Methodology

1.2 Scope of the Report

Chapter 2 – Global Systemic Lupus Erythematosus Market – Trends  

2.1 Key Trends & Developments

Chapter 3 – Global Systemic Lupus Erythematosus Market – Industry Analysis

3.1 Market Drivers

      1. High Prevalence of Autoimmune Disease
      2. Strong pipeline
      3. Increasing R&D investment on SLE drugs

           3.2 Market Restraints

      1. High use of off-label drugs
      2. Slow market uptake of Benlysta
    1. Threats and Opportunities
    2. Porter’s 5 Forces

Chapter 4 – Global Systemic Lupus Erythematosus Market – Market Analysis  

    1. 4.1. Systemic Lupus Erythematosus Market – By Drug Class
      1. Antimalarial Drugs
      2. Non-Steroidal Anti-Inflammatory Drugs
      3. Cytotoxic And Immunosuppressive Drugs
      4. Biologics
      5. Others
    2. Systemic Lupus Erythematosus Market – By Mode of Delivery
      1. Intravenous
      2. Sub-cutaneous
      3. Oral
      4. Topical
    1. Systemic Lupus Erythematosus Market – By Distribution Channel
      1. Retail pharmacies
      2. Hospitals
      3. Online Pharmacies

Chapter 5 –  Global Systemic Lupus Erythematosus Market – Geographical Analysis           

5.1. North America

5.1.1. The USA

5.1.2. Canada

5.1.3. Mexico

5.2. Europe

5.2.1. Germany

5.2.2. France

5.2.3. The UK

5.2.4. Italy

5.2.5. Spain

5.2.6. Rest of Europe

5.3. Asia Pacific

5.3.1. China

5.3.2. Japan

5.3.3. India

5.3.4. Australia

5.3.5. Rest of Asia Pacific

5.4. South America

5.4.1. Brazil

5.4.2. Argentina

5.4.3. Rest of South America

5.5 Rest of the World

Chapter 6 – Global Systemic Lupus Erythematosus Market – Competitive Landscape

6.1. Market Share Analysis

6.2. Mergers and Acquisitions Analysis

6.3. New Product Launches

Chapter 7 – Global Systemic Lupus Erythematosus Market – Company Profiles

    1. Anthera Pharmaceuticals Inc.
    2. Eli Lilly
    3. GlaxoSmithKline Plc
    4. F. Hoffmann-La Roche Ltd
    5. Pfizer Limited
    6. Sanofi
    7. Lycera Corporation
    8. Bristol-Myers Squibb
    9. ImmuPharma Plc
    10. Merck KGaA

Chapter 8 – Global Systemic Lupus Erythematosus Market – Appendix

8.1 Sources

8.2 List of Tables

8.3 Expert Panel Validation

8.4 Disclaimer

8.5 Contact Us

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!